Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Jul 31, 2019

SELL
$2.75 - $3.7 $78,718 - $105,912
-28,625 Closed
0 $0
Q1 2018

Apr 25, 2018

BUY
$2.32 - $3.44 $66,410 - $98,470
28,625 New
28,625 $79,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $661M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Brightworth Portfolio

Follow Brightworth and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brightworth, based on Form 13F filings with the SEC.

News

Stay updated on Brightworth with notifications on news.